Secukinumab (Psoriasis) - Forecast and Market Analysis to 2022

Description: Secukinumab (Psoriasis) - Forecast and Market Analysis to 2022

Summary

Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2–3% worldwide (Perera et al., 2012). Specifically, adult plaque psoriasis is the focus of this report and is defined using the 2013 International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnostic code L40.0. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking because of their immunosuppressant nature and lack of understanding as to their exact mechanism of action.

Novartis' secukinumab is a fully-human mAb that inhibits interleukin 17-A (IL-17A), which prevents the release of proinflammatory cytokines that lead to tissue destruction. IL-17A is produced by T helper 17 (TH17) cells, which originate from naïve CD4 T cells after stimulation by Transforming Growth Factor-ß (TGF-ß) and interleukin-6 (IL-6). Immune cells, such as macrophages, astrocytes, Langerhans cells, and mast cells, also produce IL-17A.

Scope

- Overview of Psoriasis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Secukinumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Secukinumab for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Psoriasis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Secukinumab performance
- Obtain sales forecast for Secukinumab from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

Contents:

1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
4 Disease Management
4.1 Treatment Overview
5 Competitive Assessment
5.1 Overview
1.2 List of Figures
Figure 1: Psoriatic Plaque on Elbow of Patient
Figure 2: The Three Layers of the Skin and Associated Structures
Figure 3: Healthy Skin Versus Psoriatic Skin
Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in Psoriasis, 2012–2022

Ordering: Order Online - http://www.researchandmarkets.com/reports/2610130/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Secukinumab (Psoriasis) - Forecast and Market Analysis to 2022
Web Address: http://www.researchandmarkets.com/reports/2610130/
Office Code: SCD2SI8V

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format Type</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 3495</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 6990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 10485</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ___________________________________________ Last Name: _______________________________________
Email Address: * ________________________________________
Job Title: ______________________________________________
Organisation: ___________________________________________
Address: _______________________________________________
City: ___________________________________________________
Postal / Zip Code: _____________________________________
Country: _______________________________________________
Phone Number: __________________________________________
Fax Number: ____________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World